Efficacy of Intensive Control of Glucose in Stroke Prevention: A Meta-Analysis of Data from 59197 Participants in 9 Randomized Controlled Trials

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Zhang, Chi ^a   Zhou, Yu Hao ^a   Xu, Chun Li ^a   Chi, Feng Ling ^a   Ju, Hai Ning ^a  

^a SHANGHAI SEVENTH PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; INSULIN GLARGINE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY MASS; CEREBROVASCULAR ACCIDENT; DISEASE CONTROL; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; FEMALE; HUMANS; MALE; MIDDLE AGED; MONITORING, AMBULATORY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RISK ASSESSMENT; STROKE;

EID: 84872825009     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054465     Document Type: Article

References (30)

1. Williams GR, Jiang JG, Matchar DB, Samsa GP, (1999) Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke 30: 2523-8.
2. Yusuf S, Reddy S, Ounpuu S, Anand S, (2001) Global burden of cardiovascular diseases, I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 104: 2746-2753.
3. Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, et al. (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373: 1765-72.
4. Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Plos Medicine 6.
5. Jadad AR, Moore RA, Carroll D, (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
6. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-88.
7. Ades AE, Lu G, Higgins JP, (2005) The interpretation of random-effects metaanalysis in decision models. Med Decis Making 25: 646-54.
8. Deeks JJ, Higgins JPT, Altman DG (2008) Analyzing data and undertaking meta-analyses. In: Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1. Oxford, UK: The Cochrane Collaboration: chap 9.
9. Higgins JPT, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-60.
10. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-34.
11. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, et al. (1996) Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. Eur Heart J 17: 1337-1344.
12. The NAVIGATOR Study Group (2010) Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events.N Engl J Med. 362: 1463-76.
13. the VADT Investigators, (2009) Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes.N.Engl J Med. 360: 129-39.
14. The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 358: 2545-59.
15. The ADVANCE Collaborative Group (2008) Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 358: 2560-72.
16. the PROactive investigators, (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279-89.
17. The ORIGIN Trial Investigators, (2012) Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. N Engl J Med 367(4): 319-28.
18. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-53.
19. The RECORD Study Team (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373: 2125-35.
20. Emerging Risk Factors Collaboration, (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375(9733): 2215-22.
21. Wang X, Qin X, Demirtas H, Li J, Mao G, et al. (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369: 1876-82.
22. Webb AJ, Fischer U, Mehta Z, Rothwell PM, (2010) Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis.Lancet. 375: 906-15.
23. Cholesterol Treatment Trialists (CTT) Collaborators (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380: 581-90.
24. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-65.
25. (DCCT/EDIC) Study Research Group (2005) Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. N Engl J Med 353: 2643-53.
26. Wilcox R, Bousser MG, Betteridge DJ, (2007) Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke: Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVasculalr Events 04). Stroke 38: 865-873.
27. The GIST Trialists Collaboration, (2007) Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 6: 397-406.
28. The Diabetes Prevention Program Research Group (2005) Impact of Intensive Lifestyle and Metformin Therapy on Cardiovascular Disease Risk Factors in the Diabetes Prevention Program. Diabetes Care 28: 888-894.
29. Goff DC Jr, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, et al. (2007) Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99: 4i-20i.
30. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL,et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141: 421-31.